Cenetri Publishing Group takes keen delectation and highly regarded to host a captivating scientific meeting 2nd International Conference on Oncology & Cancer Science, August 06-08, 2018 at Berlin, Germany.International Conference on Oncology & Cancer Science presents a unique occasion to meet prominent surgeons, doctors, academician, scientists and specialists across the globe and listen to best speakers on new expansions that will influence and spread the future of Cancer Science and Oncology. The conference will unite the endeavours made all over the world to spread the field of Health through speakers and suppliers who are recognized world leaders in this area of specialization.
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A medical professional who practices oncology is an oncologist. Cancers are often managed through discussion on multi-disciplinary cancer conferences where medical oncologists, surgical oncologists, radiation oncologists, pathologists, radiologists and organ specific oncologists meet to find the best possible management for an individual patient considering the physical, social, psychological, emotional and financial status of the patient. It is very important for oncologists to keep updated with respect to the latest advancements in oncology, as changes in management of cancer are quite common. All eligible patients in whom cancer progresses and for whom no standard of care treatment options are available should be enrolled in a clinical trial.
Cancer continues to be one of the leading causes of morbidity and mortality worldwide, but therapeutic innovation based on enhanced sympathetic of disease biology and translational research have considerably rehabilitated the treatment pattern for many cancers. From 2011 to 2016, 68 new drugs have been approved for 22 indications. Personalized oncology medicines, targeted agents and novel immunotherapy agents can provide significant clinical benefit and have raised the hope of considerably improving cancer survival across a large number of tumor types.
Oncology continues to be an area of active interest with a robust pipeline of over 600 molecules in late stage development of which 90% is a targeted therapy. At the same time, newer treatment options, containing biomarker-based patient segmentation and availability of biomarker-based treatment approaches, have added to treatment complexity. Novel oncology treatments are reaching physicians quicker than ever, but the availability of newly launched agents differs substantially by geography.
Global overheads of oncology therapeutics and supportive care drugs increased from $91Bn in 2012 to $113Bn in 2016, with the United States accounting for 46% of the total global oncology costs. Extended duration of therapy with novel agents, use of combination therapies with high cost novel agents and the possibility of patients getting various lines of therapies are factors likely to contribute to further increase in costs. Approval of newer agents and increasing use of older branded drugs are the contributing factors for increase in costs in other regions.